Clinical trial
A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
NCT05657860 is registered in ClinicalTrials.gov with Maimonides Medical Center as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome
- Lead sponsor
- Maimonides Medical Center
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- December 17, 2020
- Completion date
- December 16, 2023
- Enrollment
- 15 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
abnormalities, multiple, aggression, antihypertensive agents, behavioral symptoms, chromosome disorders, congenital abnormalities, genetic diseases, inborn, intellectual disability, molecular mechanisms of pharmacological action, nervous system diseases, neurobehavioral manifestations, neurologic manifestations, neurotransmitter agents, nutrition disorders, obesity, overnutrition, pathologic processes, physiological effects of drugs, prader-willi syndrome, self-injurious behavior, skin-picking